2.48
前日終値:
$2.43
開ける:
$2.45
24時間の取引高:
3.18M
Relative Volume:
0.76
時価総額:
$607.34M
収益:
$194.75M
当期純損益:
$-51.26M
株価収益率:
-8.8571
EPS:
-0.28
ネットキャッシュフロー:
$-23.38M
1週間 パフォーマンス:
+6.90%
1か月 パフォーマンス:
+50.30%
6か月 パフォーマンス:
+29.17%
1年 パフォーマンス:
+92.25%
Akebia Therapeutics Inc Stock (AKBA) Company Profile
名前
Akebia Therapeutics Inc
セクター
電話
617-871-2098
住所
245 FIRST STREET, CAMBRIDGE, MA
AKBA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
AKBA
Akebia Therapeutics Inc
|
2.48 | 607.34M | 194.75M | -51.26M | -23.38M | -0.28 |
![]()
ZTS
Zoetis Inc
|
160.41 | 66.72B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
HLN
Haleon Plc Adr
|
10.45 | 48.08B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 47.74B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.48 | 18.49B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
308.07 | 13.31B | 2.99B | 1.21B | 1.13B | 25.06 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-28 | 開始されました | Leerink Partners | Outperform |
2025-04-01 | 開始されました | Jefferies | Buy |
2023-11-29 | 再開されました | BTIG Research | Buy |
2023-08-28 | アップグレード | H.C. Wainwright | Neutral → Buy |
2023-05-31 | アップグレード | Piper Sandler | Neutral → Overweight |
2022-03-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2022-03-31 | ダウングレード | Mizuho | Buy → Neutral |
2022-03-31 | ダウングレード | Needham | Buy → Hold |
2022-03-31 | ダウングレード | Piper Sandler | Overweight → Neutral |
2021-03-08 | 開始されました | Cantor Fitzgerald | Overweight |
2021-01-29 | ダウングレード | JP Morgan | Neutral → Underweight |
2019-11-14 | 繰り返されました | Needham | Buy |
2019-08-06 | 繰り返されました | H.C. Wainwright | Buy |
2019-07-11 | 繰り返されました | H.C. Wainwright | Buy |
2019-05-02 | 開始されました | JP Morgan | Overweight |
2019-03-20 | 開始されました | Citigroup | Neutral |
2018-09-07 | 再開されました | Morgan Stanley | Equal-Weight |
2018-08-10 | 繰り返されました | Needham | Buy |
2018-06-06 | 繰り返されました | H.C. Wainwright | Buy |
2017-12-19 | 開始されました | Piper Jaffray | Overweight |
2017-12-07 | 開始されました | BTIG Research | Buy |
2017-09-15 | 開始されました | RBC Capital Mkts | Sector Perform |
2017-07-10 | 繰り返されました | H.C. Wainwright | Buy |
2017-04-27 | 繰り返されました | H.C. Wainwright | Buy |
2017-04-27 | 繰り返されました | Needham | Buy |
2016-12-27 | 繰り返されました | H.C. Wainwright | Buy |
2016-12-20 | 繰り返されました | JMP Securities | Mkt Outperform |
2016-11-15 | 開始されました | Aegis Capital | Buy |
2016-09-29 | 開始されました | Brean Capital | Buy |
2016-03-16 | 繰り返されました | Needham | Buy |
2016-01-21 | 開始されました | Credit Suisse | Neutral |
すべてを表示
Akebia Therapeutics Inc (AKBA) 最新ニュース
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - GlobeNewswire
Akebia projects Vafseo rollout to double patient access by Q4 2025 - MSN
Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
Akebia Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2025 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics: Q1 Earnings Snapshot - New Haven Register
Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ... - Yahoo Finance
Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ... By GuruFocus - Investing.com Canada
Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and Strategic Market Penetration - GuruFocus
Akebia Therapeutics Reports Strong Q1 2025 Performance - TipRanks
Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Akebia Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Transcript : Akebia Therapeutics, Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Akebia Therapeutics (AKBA) Sees Strong Q1 Revenue Growth Fueled by Vafseo - GuruFocus
Akebia Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Akebia Therapeutics beats Q1 2025 estimates, stock surges - Investing.com Australia
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Akebia (AKBA) Surpasses Revenue Expectations with Strong Vafseo Debut | AKBA Stock News - GuruFocus
Akebia Therapeutics Inc Q1 2025 Earnings: EPS of $0.04, Revenue Surges to $57.3 Million, Beating Estimates - GuruFocus
Akebia Therapeutics, Inc. SEC 10-Q Report - TradingView
Akebia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Earnings To Watch: Akebia Therapeutics Inc (AKBA) Reports Q1 2025 Result - Yahoo Finance
Akebia Therapeutics Announces Multiple Positive Business Updates - ADVFN
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 38% Share Price Rise - simplywall.st
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease - ADVFN
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights - marketscreener.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics Expands Team: Grants $2.41 Stock Options to 8 New Strategic Hires - Stock Titan
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Akebia Therapeutics, Inc. Announces First Quarter 2025 Financial Results Release and Conference Call Details - Nasdaq
Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business ... - Bluefield Daily Telegraph
Akebia (AKBA) Secures Strong Position with Vafseo Launch for Ane - GuruFocus
Leerink raises Akebia stock to outperform with $7 target By Investing.com - Investing.com Canada
Leerink Partners Initiates Coverage of Akebia Therapeutics (AKBA) with Outperform Recommendation - Nasdaq
Akebia (AKBA) Secures Strong Position with Vafseo Launch for Anemia Treatment | AKBA Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - ADVFN
Lobbying Update: $45,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Nasdaq
Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock - Barchart.com
US High Growth Tech Stocks to Watch in 2023 - Yahoo Finance
Akebia Therapeutics : Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones - MarketScreener
Akebia Therapeutics gets EU positive recommendation for Xoanacyl - MSN
Akebia Therapeutics Announces Positive Opinion of European - GlobeNewswire
EMA panel endorses Akebia’s kidney disease treatment By Investing.com - Investing.com Australia
EMA panel endorses Akebia’s kidney disease treatment - Investing.com India
Akebia Therapeutics Says EMA Panel Recommends Approval of Xoanacyl for Chronic Kidney Disease Treatment - MarketScreener
Akebia Therapeutics Inc (AKBA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):